

David Rosenberg

David Rosenberg is Vice President of IP Policy at GlaxoSmithKline.

He has responsibility for managing the development of GSK's position on many IP policy issues.

He represents GSK on various industry bodies and UK and European cross-industry organisations. He chairs the IP Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

David was closely involved in the enquiry into the pharmaceutical sector carried out by DG Competition of the European Commission, which concluded in 2009. He has also been closely involved in discussions with the UK Intellectual Property Office and the European Commission, relating to the creation of a unitary European Patent and Unified Patent Court.

For several years, he has been engaged in discussions around the Nagoya Protocol and the EU implementing Regulation.

David is a regular speaker and occasional author on these issues. He has twice been named one of the "50 Most Influential People in IP" by *Managing Intellectual Property*.

David has a law degree from Exeter University. Before qualifying as a solicitor he spent three years doing legal research and teaching in the UK and US. David joined GlaxoWellcome in February 2000 after 12 years in the IP Group at Clifford Chance where undertook IP litigation and transactional work.